Cancer Prevention & Research Institute of Texas, RP200058

Enhancing Cytarabine Response Through SAMHD1 Inhibition

San Antonio Partnership for Precision Therapeutics

Development of antiviral therapies against Nipah and Hendra viruses

San Antonio Partnership for Precision Therapeutics

Blocking SARS-CoV-2 Evasion from Innate Antiviral Defenses  

San Antonio Partnership for Precision Therapeutics

Role of FURIN in COVID-19 and Underlying Molecular and Immunological Mechanisms

San Antonio Partnership for Precision Therapeutics

Mechanism-Based Targeting of an RNA Processing Pathway

NIH 5UL1TR002645 (P.I. Core Facility)

Institution for the Integration of Medicine and Science: A Partnership to Improve Health CTSA Optional Core Facility Grant 

Department of Defense CDMRP, PR171296                                               

Protein Kinase C Epsilon Inhibitors to Treat Pain. Collaboration with UT Austin and UC San Francisco

Cancer Prevention & Research Institute of Texas, RP160844                                           

Center for Innovative Drug Discovery: Enhancement of a Shared Cancer Resource for South Texas. Collaboration with UT Health San Antonio.

Greehey Children’s Cancer Center Pilot Award, SAT0002969

Validation and Development of PROTAC’s for Pediatric Cancers

National Institutes of Health R01 AI119554

Development of novel chemical series of Candida albicans biofilm inhibitors. Collaboration with Jose Lopez Ribot (UTSA). 

National Institutes of Health R01 AI115691

Structure-guided redesign of an antischistosomal drug. Collaboration with UT Health San Antonio and Texas BioMed. 

NIH U54 Mays Cancer Center Pilot Program Grant  

Treatments for Pediatric Liver Tumors 

San Antonio Medical Foundation Grant

A High-Throughput, High-Content Screen of iPSC-Derived Dopaminergic Neurons for Neuroprotective Compounds

IIMS/CTSA (NIH) pilot award, NIH 5UL1TR002645

“Development of novel FAAH Inhibitors for the Treatment of Schizophrenia”. Collaboration with UT Health San Antonio

Cancer Prevention & Research Institute of Texas, DP150055

Druggable Targets that Regulate the Antitumor Activity of ER-beta.  Collaboration with UT Health San Antonio. 

Department of the Army, Medical Research, PR141776

Discovery of Novel N-Nicotinamide Methyltransferase Inhibitors to Combat Obesity-Linked Osteoarthritis and Metabolic Disease among Veterans and Beneficiaries.  Collaboration with UTMB Galveston.

IIMS/CTSA (NIH) pilot award. NIH 5UL1TR002645 

Discovery of novel inhibitors of oncoprotein EYA2 in breast and ovarian cancers.  Collaboration with UT Health San Antonio.